IAMA Therapeutics Secures €15M for Autism Drug Trials
Deal News | Apr 16, 2025 | CDP Venture Capital
IAMA Therapeutics has successfully secured €15 million in funding from CDP Venture Capital. This investment is aimed at initiating phase 2 clinical trials of their promising drug candidate, IAMA-6, designed to potentially enhance the lives of individuals on the autism spectrum. The funds will facilitate the development and rigorous testing required to advance the drug along the regulatory pathway, bringing it one step closer to market readiness. This milestone highlights the growing interest and investment in innovative medical solutions targeting autism spectrum disorders, as IAMA Therapeutics continues its efforts to bring meaningful change to patient care.
Sectors
- Pharmaceuticals & Biotechnology
- Venture Capital
Geography
- Italy – CDP Venture Capital is an Italian firm, indicating the geographical origin of the funding and the likely base of IAMA Therapeutics.
Industry
- Pharmaceuticals & Biotechnology – The article discusses the development of a pharmaceutical product by IAMA Therapeutics, focusing on autism treatment.
- Venture Capital – CDP Venture Capital's involvement highlights the role of venture capital funding in developing new medical therapies.
Financials
- €15 million – The amount invested by CDP Venture Capital to fund phase 2 clinical trials for IAMA Therapeutics' drug IAMA-6.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| IAMA Therapeutics | Target | Company | A biotech firm focused on developing therapies for neurological conditions, including autism. |
| CDP Venture Capital | Investor | Company | An Italian venture capital firm investing in innovative companies, supporting IAMA Therapeutics' new drug trials. |